Brain Cancer Halted in Mice Using Antihistamine Drug

Glioblastoma is the most prevalent and also the most lethal type of brain tumour in adults, with no curative treatment currently available. Glioblastomas cannot be surgically completely excised, as the tumour cells are adept at invading tissues and spreading around the brain. In addition, glioblastoma cells are extremely resistant to existing drug therapies. For a long time, researchers have been...

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based therapy for the treatment of chronic hepatitis B virus (HBV) infection in adults. The Company anticipates human proof-of-concept data from the Phase 1 trial, which is known as DCR-HBVS-101, in the fourth quarter of 2019. In January...

Nabriva Therapeutics Submits Marketing Authorization App for Lefamulin to Treat Community-Acquired Pneumonia

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the Company’s  marketing authorization application (MAA) for both the intravenous (IV) and oral formulations of lefamulin, a potentially first-in-class, semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired pneumonia (CAP) in adults 18 years of age and older, has been submitted to...

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma

Celgene plans to submit sNDA by end of 2019 Celgene plans additional studies with the AIDS Malignancy Consortium in U.S. and sub-Saharan Africa Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® (pomalidomide) for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi...

Three-antibiotic cocktail clears ‘persister’ Lyme bacteria in mouse study

A new study from researchers at the Johns Hopkins Bloomberg School of Public Health found that a slow-growing variant form of Lyme bacteria caused severe symptoms in a mouse model. The slow-growing variant form of Lyme bacteria, according to the researchers, may account for the persistent symptoms seen in ten to twenty percent of Lyme patients that are not...

University of Texas finds strong link to elevated blood sugar and fibromyalgia pain in metformin trial

Researchers led by a team from The University of Texas Medical Branch at Galveston were able to almost completely eliminate pain in fibromyalgia patients with a medication that targets insulin resistance ( metformin ), showing a link to elevated blood sugars and the disease. The study consisted of two groups, one on the standard treatment that involves norepinephrine reuptake...

Medivir’s MIV-711 therapy for osteoarthritis shows disease modifying activity in phase 2 extension trial

Medivir presented the data on their Cathepsin K Inhibitor, MIV-711, at the OARSI conference over the weekend, and the results were a bit of a mixed bag but generally positive. Most therapies that regenerate cartilage and/or bone consist of single or multiple injections into the affected joint, and are long acting. Many of these therapies use growth factors, stem cells,...

New Approach to Battling Antibiotic Resistant Bacteria Targets Bacterial DNA to Weaken Bacteria’s Defenses

Researchers at Jefferson University have been experimenting with ways to weaken the defenses of antibiotic resistant bacteria, by targeting a common feature of the resistant bacteria - a pair of membranes which are able to expel antibiotics by pumping them out of the cell. The researchers found a way to interfere with transfer RNA that is unique to the bacteria,...